Clinical Data, Inc. Announces Expanded Reimbursement For Its FAMILION® Long QT Syndrome Genetic Test

Clinical Data, Inc. (NASDAQ:CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced that its PGxHealth? division has achieved significant growth in positive reimbursement policies for its FAMILION® genetic test for Long QT Syndrome (LQTS).

More: continued here

Filed under: Clinical Trials on March 3rd, 2008